ArticleWorld journal of psychiatry2025
Optimizing perimenopausal mental health by integrating precision biomarkers, digital health interventions, and psychosocial care.
Article in World journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Then and Now: What We Have Learned From the WHI.The Journal of clinical endocrinology and metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study addressed the critical need for an integrated, personalized approach to perimenopausal mental health, addressing both biological and psychosocial factors. Current research highlighted the influence of hormonal fluctuations, genetic predispositions, and lifestyle factors in shaping perimenopausal mental health outcomes. This transitional period is marked by significant hormonal fluctuations contributing to heightened anxiety, depression, and sleep disturbances, affecting the women's quality of life. Traditional pharmacological treatments, including selective serotonin reuptake inhibitors and hormone replacement therapy, have limitations due to variable efficacy and side effects, emphasizing the need for precision medicine. Advancements in pharmacogenomics and metabolomics provide new avenues for individualized treatments, with genetic markers
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.